TRVN - Trevena, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3100
0.0000 (0.00%)
At close: 4:00PM EDT

1.3300 +0.02 (1.53%)
After hours: 4:54PM EDT

Stock chart is not supported by your current browser
Previous Close1.3100
Open1.2900
Bid1.3100 x 1300
Ask1.3300 x 3000
Day's Range1.2600 - 1.3400
52 Week Range0.3820 - 3.5780
Volume688,292
Avg. Volume1,603,214
Market Cap120.983M
Beta (3Y Monthly)5.51
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire11 days ago

    Trevena Reports First Quarter 2019 Results

    — Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine — – Study on track to initiate by end of June – Company to.

  • GlobeNewswirelast month

    AMAG Pharmaceuticals Appoints New Members to Board of Directors

    “We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.

  • ACCESSWIRE2 months ago

    Watch These Four Healthcare Stocks Set The Pace On Tuesday

    Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.

  • GlobeNewswire2 months ago

    Trevena Reports Fourth Quarter and Full Year 2018 Results

    — Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA —  — Successful fundraising extends cash runway into 3Q 2020 —Company to.

  • GlobeNewswire2 months ago

    Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain

    The publication, “APOLLO-1: A randomized placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein–biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy,” with lead author, Eugene R Viscusi, M.D.,Professor of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, is available online at https://www.dovepress.com/journal-of-pain-research-archive41. “In this study, oliceridine was found to provide relief that was statistically superior to placebo in patients with moderate-to-severe acute post-surgical pain,” said Dr. Viscusi.

  • ACCESSWIRE3 months ago

    These Four Tech Stocks Could Test March Highs

    As we've seen over the last few years, tech companies have invested resources in artificial intelligence, automation, quantum computing, and augmented reality to pioneer technologies to drive society into the future. ParcelPal Technology Inc (PTNYF) (PKG), Trevena Inc (TRVN), China Finance Online Co. Limited (JRJC), and Luna Innovations Incorporated (LUNA) represent 4 tech stocks on the rise on Monday. The Company is focused on improving the lives of their customers through their on-demand marketplace where customers can purchase what they need and have their goods delivered within an hour.

  • GlobeNewswire3 months ago

    Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019

    CHESTERBROOK, Pa., March 04, 2019 -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.

  • ACCESSWIRE3 months ago

    Biotech Stocks Set to Pop

    HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...

  • ACCESSWIRE3 months ago

    Top Cannabis and Biotech Stocks To Watch

    HENDERSON, NV / ACCESSWIRE / February 6, 2019 / Cannabis and Biotech are in the middle of a massive comebacks, several small-cap plays in the sectors are prime for investors, here's a few to start researching. ...

  • GlobeNewswire3 months ago

    Trevena to Present at the 21st Annual BIO CEO & Investor Conference

    CHESTERBROOK, Pa., Feb. 05, 2019 -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.

  • GlobeNewswire4 months ago

    Market Trends Toward New Normal in CoreLogic, Nasdaq, Nevro, Blue Apron, Unisys, and Trevena — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE4 months ago

    Opioid Abuse and Dependent Therapies, Here is What Travena is Doing to Tackle this Problem

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive report on Trevena, Inc. (TRVN), a biopharmaceutical company that has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. The management strongly believes in the utility of oliceridine as a new analgesic option for the management of moderate to severe acute pain for patients in hospitals or other controlled clinical settings and has laid out a detailed plan to capitalize this opportunity and gain approval for Oliceridine. Trevena was founded to translate Nobel Prize-winning research into a new generation of ground-breaking medicines.

  • GlobeNewswire4 months ago

    Trevena Announces $10 Million Registered Direct Offering of Common Stock

    Trevena, Inc. (TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, pursuant to which Trevena agreed to sell to the purchasers an aggregate of 10,000,000 shares of its common stock at an offering price of $1.00 per share, in a registered direct offering, for gross proceeds of $10.0 million, before deducting placement agent fees and offering expenses payable by Trevena. The offering is expected to close on or about February 1, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Looking For A Healthy Start On Monday (1/28/19)

    With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. As an industry predicated on improving the quality of life for consumers, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Trevena Inc (TRVN), and Teladoc Health Inc (TDOC) represent four healthcare companies determined to invest in the betterment of the global health market. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • GlobeNewswire4 months ago

    Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine

    CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --  Trevena, Inc. (TRVN) today announced the receipt of the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the oliceridine New Drug Application (NDA).

  • GlobeNewswire5 months ago

    National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that TRV734 data were featured in a presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology as part of Trevena’s ongoing collaboration with the National Institute on Drug Abuse (NIDA). The presentation, entitled “Modeling Opioid Maintenance Therapy in Rats: Effects of Chronic Buprenorphine and the Biased Mu-Opioid Receptor Agonist TRV130 on Relapse to Oxycodone Seeking,” was delivered by Yavin Shaham, Ph.D., Chief, Behavioral Neuroscience Research Branch, Intramural Research Program at NIDA.

  • GlobeNewswire5 months ago

    Report: Developing Opportunities within Exelixis, Cintas, BGC Partners, FirstEnergy, Hologic, and Trevena — Future Expectations, Projections Moving into 2018

    NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    SHAREHOLDER ALERT: TRVN GOOG GOOGL CWH HON FIT SYF RYAAY TSRO MGI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Dec. 10, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.

  • GlobeNewswire5 months ago

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

  • GlobeNewswire5 months ago

    SHAREHOLDER ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Trevena, Inc. (TRVN) & Lead Plaintiff Deadline - December 10, 2018

    Attorney Advertising--(PR Newswire)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Trevena, Inc. (“Trevena” or the “Company”) (TRVN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Trevena securities between May 2, 2016 and October 8, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/trvn. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants misled shareholders to believe that the April 28, 2016 End-of-Phase 2 Meeting with the United States Food and Drug Administration (“FDA”) was more successful than it really was.

  • GlobeNewswire5 months ago

    Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced the promotion of Robert T. Yoder from Vice President Commercial Operations and Sales to the newly created position of Senior Vice President and Chief Business Officer, effective immediately. Mr. Yoder brings to this position over 30 years of industry experience across a wide range of functions and therapeutic areas, including acute care. “Since joining Trevena in June, Bob has taken on increasing leadership within the Company and has played a large role in our efforts towards the ultimate approval of oliceridine,” said Carrie L. Bourdow, President and Chief Executive Officer.

  • ACCESSWIRE5 months ago

    FINAL DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Reminds Investors with Losses in Excess of $200,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / December 7, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (''Trevena'' or ''the Company'') (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between May 2, 2016 and October 8, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before December 10, 2018.

  • Business Wire5 months ago

    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Trevena, Inc. to Contact the Firm

    Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Trevena, Inc. (“Trevena” or the “Company”) (TRVN) of the December 10, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Trevena stock or options between May 2, 2016 and October 8, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/TRVN.

  • GlobeNewswire5 months ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, GOOG, NKTR and RYAAY

    NEW YORK, Dec. 07, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.

  • Business Wire5 months ago

    MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Trevena, Inc. (“Trevena” or “the Company”) (NASDAQ: TRVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.